Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16815507 | 0.89 | LPL (0.43) | LPLLIPGROCK1CSF1REGFR | |
| SCHEMBL1331278 | 0.87 | LPL (0.42) | LPLLIPGROCK1CSF1REGFR | |
| SCHEMBL578694 | 0.84 | LPL (0.40) | LPLLIPGCSF1RCA1CA2 | |
| SCHEMBL142144 | 0.83 | LPL (0.49) | LPLLIPGROCK1CSF1REGFR | |
| SCHEMBL25340242 | 0.83 | LPL (0.36) | LPLLIPGROCK1CSF1RCA1 | |
| SCHEMBL29509764 | 0.83 | LPL (0.36) | LPLLIPGROCK1CSF1RCA1 | |
| SCHEMBL15968930 | 0.83 | AAK1 (0.49) | LPLLIPGCSF1REGFRCA1 | |
| SCHEMBL3192898 | 0.82 | LIPG (0.45) | LPLLIPGROCK1EGFRAAK1 | |
| SCHEMBL28624112 | 0.82 | LPL (0.42) | LPLLIPGROCK1EGFRCA1 | |
| SCHEMBL14994486 | 0.81 | HIF1A (0.39) | LPLLIPGCSF1RCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418203-B1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO CO LTD (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | BMP2, BMP4, BMP6 | LPL 2204/4885LIPG 1246/4885ROCK1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.